White House rule would expand coverage of anti-obesity drugsÂ
The proposed rule from the Department of Health and Human Services seeks to expand when Medicare and Medicaid can cover anti-obesity drugs known as GLP-1 inhibitors, sold as Zepbound, Ozempic, Mounjaro